Trials / Completed
CompletedNCT01729819
Interventional Clinical Trial in Patients in Overactive Bladder With Nocturia in Women
A Multi-centre, Double-blind, Randomised Trial Investigating the Efficacy and Safety of a Combination Therapy, Desmopressin and Tolterodine, for Treatment of Overactive Bladder With Nocturia in Women
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 106 (actual)
- Sponsor
- Ferring Pharmaceuticals · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the trial is to investigate the efficacy of combining tolterodine and desmopressin compared with tolterodine monotherapy in the treatment of women with overactive bladder with nocturia in terms of reduction of nocturnal voids during 3 months of treatment
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tolterodine tartrate extended release capsules | |
| DRUG | Desmopressin orally disintegrating tablets | |
| DRUG | Placebo orally disintegrating tablets |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2014-11-01
- Completion
- 2014-11-01
- First posted
- 2012-11-20
- Last updated
- 2018-09-12
- Results posted
- 2018-08-14
Locations
24 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01729819. Inclusion in this directory is not an endorsement.